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ABSTRACT 
Back ground: Metabolic syndrome (MetS) is a complex disorder which is characterized by 
clustering of interrelated risk factors of cardiovascular disease and diabetic mellitus. So far, 
cutoff point variability for one of the cluster to define MetS, which is waist circumference, based 
on ethnicity was documented.  
Objective: To determine waist circumference cutoff point to define MetS among type II diabetic 
patients.  
Methods: Institution based cross sectional study was conducted from March to April 2017 at 
Ayder Comprehensive Specialized Hospital among type II diabetic mellitus (T2DM) patients. 
Systematic sampling technique was used to select study participants and 520 of them were 
assumed to be included in the study. Data were collected by checklist, anthropometric 
measurements and biochemical analyses. Fasting blood sample was collected for the biochemical 
evaluation. Data were entered to Epi-info 3.5.1 and transferred to SPSS 20 for analysis. 
Participants having more than one abnormal MetS components were categorized as cases. The 
classification power of waist circumference (WC) to distinguish cases from controls was 
determined by ROC curve analysis. WC cutoff point was determined by taking the point which 
was having maximum Youden Index. 
Results: A total of 520 participants were included in the study, of whom 308(59.2%) were 
females. The mean age of the participants was 56 ± 10.8 years and 55 ± 11.4 years for males and 
females respectively. The classification power of WC was 0.67 (0.58-0.75) for male and 0.63 
(0.52-0.73) for females. The optimal waist circumference cutoff point to predict the presence of 
at least two other components of the MetS was 95.5 cm (sensitivity 39.8%, specificity86.3%, p  
value < 0.001) for males and 87.5 cm (sensitivity73.1%, specificity54.5%, p  value < 0.017) for 
females. 
Conclusion: The power of WC value to classify cases from controls was poor and the cutoff 
points of WC were 87.5 cm and 95.5 cm for female and male respectively. WC cutoff points 
need to be reconsidered for these patients using a prospective cohort study. In addition, studies 
which can consider the confounders such as lipid lowering medications, age of the participants 
and duration of diabetes are advisable in order to increase the classification power of WC.  
Keywords:  Diabetic mellitus; Metabolic syndrome; Waist circumference 
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1. INTRODUCTION  
1.1 Background 
Metabolic syndrome (MetS) is a complex disorder which is characterized by clustering of a 
number of interrelated risk factors that increase the risk of cardiovascular disease (CVD), type II 
diabetic mellitus (T2DM) and other non communicable diseases. The probability of risk is 
increasing when they appear together (1) and even it increases the complication rate when it 
combines with DM (2) . 
Historically, cluster of MetS were including insulin resistance, hypertension, triglyceridemias, 
reduced high density lipoprotien cholesterol (HDL-c), shifting of low density lipoprotien (LDL-
c) to small dense particles,  increased procoagulant state, increased vascular abnormalities, 
increased inflammatory markers, and hyperuricemia. However, today various international 
organizations have defined MetS using five components alone including elevation of waist 
circumference (WC), blood pressure (BP), triglycerides(TG), fasting blood glucose(FBG), and 
reduced HDL-c level (3). 
Elevated WC is one of the components of MetS. It is accumulation of fat in the central region of 
the body. It is commonly associated with insulin resistance and it is evident that the abdominal 
fat accumulation plays a central role for pathogenesis of MetS (4).  
The fundamental cause of obesity and overweight is an energy imbalance between calories 
consumed and calories expended (5). Factors that contribute to the preferential accumulation of 
fat in certain body regions as well to the development of insulin resistance involve modifiable 
(physical activity levels, nutritional surplus and hormonal status) and non-modifiable factors 
(age, gender, genetic predisposition and ethnic background)(6). 
Compared to the subcutaneous fat, the visceral abdominal fat confers more risk of metabolic and 
cardiovascular complications. This may be explained by, visceral fat has a six times higher 
lipolytic activity which directly releases free fatty acids into the portal circulation, and this 
considerably contributes to insulin resistance (7).  
To precisely assess the visceral fat volume, abdominal computed tomography (CT) has been 
considered as the most accurate and reproducible technique (8). However, CT scans are costly 
and time consuming, and exposes to ionizing radiation (9). Because of this limitation a variety of 
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alternative methods are being used to assess abdominal obesity. Waist to hip ratio, WC and body 
mass index (BMI) had good correlation with abdominal imaging. Among them, WC is 
considered to be simple and inexpensive measure with excellent correlation with CT (10). In 
addition, it is used to define MetS based on various organizational criteria and different scholars 
indicted that WC appears to be a better central obesity indicator than BMI and waist to hip ratio 
(11).  
World Health Organization (WHO) recommends BMI, but all organizations and expert groups 
uses WC as one of the criteria to define MetS. International Diabetic Federation (IDF), 
particularly, needs elevation of WC as obligatory criteria with different cutoff point in 
accordance with ethnicity and gender. Different literatures also supported that WC cutoff point is 
much variable among different ethnic groups and between genders. However, based on ethnicity 
and gender, until now, IDF have stated WC cutoff point for the general populations to two 
regions alone to define MetS, for the European and Asian populations.  
The African region had no cutoff point for WC to define MetS yet because there is lack of 
representative data (12). However, different literatures supported that WC cutoff point is much 
variable among different ethnic groups and between genders. Different literatures also support 
the necessity of local based WC cutoff points in the study among T2DM patients. Consequently, 
due to lack of properly determined WC cut points among T2DM patients in our population, we 
decided to determine WC cut points to define MetS among T2DM patients in Ayder 
Comprehensive Specialized Hospital, Mekelle University, Tigray Region, Northern Ethiopia. 
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 1.2 Statement of the problem 
Elevated WC is one of the major components of MetS and it is also positively associated with 
the development of chronic non-communicable diseases (NCDs) such as CVDs, T2DM, 
musculoskeletal disorders and cancers. Those diseases have been reported as the major causes of 
death globally and they accounted for 36 million (63 %) of the 57 million deaths in 2008(13, 14).  
From recent estimates of the IDF, the number of adults with diabetes in the world currently 
stands at 415 million. An estimated 14.2 million people aged 20–79 have diabetes in the sub-
Saharan Africa (SSA) region; by 2040 this figure will be more than double (15). In developing 
countries, mainly in Asia and Africa, DM  may represent as much as 70% of all cases and about 
90 – 95% of the diabetes cases are T2DM (16). In 2015, over 1.33 million cases were diabetes in 
Ethiopia. Of these,  23,145 deaths of adults aged 20-79 were  due to diabetes  (17). 
In addition,  obese people are at increased risk for many serious diseases and health conditions 
including  mental illness such as clinical depression, anxiety, and other mental disorders(18, 19). 
Obese people are also at higher risk for body pain and difficulty with physical functioning as 
compared to non obese individuals (20). 
Worldwide prevalence of overweight and obesity is increasing at an alarming rate in developed 
and developing countries, and they become a major global health challenges (21, 22).  In 2014, 
more than 1.9 billion adults aged 18 years and older were overweight. Of these over 600 million 
adults were obese. Overall, about 13% of the world’s adult populations (11% of men and 15% of 
women) were obese and 39% of adults (38% of men and 40% of women) were overweight. The 
worldwide prevalence of obesity was more than doubled between 1980 and 2014 (5).  The 
highest prevalence of overweight and obesity was also recorded in African region particularly in 
South African and Ugandan (23, 24). Economic globalization and western life style in 
developing countries have driven changes in dietary patterns and food choices (25). According to 
the 2013 Global Burden of Disease study, obesity is already a major public health challenge in 
many middle income countries such as in Kenya; It was estimated that about 36% and 49 % of 
men and women aged 20 years or older, respectively are either overweight or obese (23). 
Obesity is prevalent in patients with type II diabetic mellitus. In some area such as in United 
kingdom, approximately 86% of patients with T2DM are overweight or obese (26). In Australia 
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53% of patients with T2DM are obese and 32.8% are overweight (27). In Saudi Arabia, the 
prevalence of overweight among patients with T2DM is around 87.5% (28).  
Obesity has an economical implication of once country. It has direct consequence in medical 
spending on diagnosis and treatment of obesity related diseases. The indirect consequence also 
involves loss of productivity due to increased death and illness, and the need for informal care. 
(29). 
It is estimated that around 20-25 % of the world’s adult population have MetS and they are twice 
as likely to die from and three times as likely to have a heart attack or stroke compared with 
people without the syndrome (30). MetS is extremely common among diabetic patients and it is a 
risk factor for the development of diabetes and its complications (31). In addition, people with 
MetS have a fivefold greater risk of developing T2DM patients (32). In 2004, MetS was present 
in 25.2% of T2DM patients in Nigeria(33). In sub-Saharan Africa, 71.1% of T2DM patients had 
MetS, the prevalence was significantly higher in women than in men (34).  
Measurement of abdominal obesity is strongly associated with increased cardiometabolic risk, 
cardiovascular events, and mortality. A normal WC differs for specific ethnic groups due to 
different cardiometabolic risk. For example, Asians have increased cardiometabolic risk at lower 
body mass indexes and with lower waist circumferences than other populations (35). 
Despite elevated WC being one of the basic components of MetS, the real value of WC hadn’t 
been estimated in T2DM of the study area. Absence of WC cutoff point in our population may 
affect estimation for prevalence of MetS. As a result, the aim of this study was to determine WC 
cutoff point for defining MetS in T2DM patients in Ayder Comprehensive Specialized Hospital, 
Tigray Region, Northern Ethiopia. 
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1.3. Literature review   
According to the harmonized definition for MetS, the optimal WC cutoff point to predict the 
presence of at least two other components of MetS is ≥94 cm and ≥80cm for Europeans, ≥90cm 
and ≥80cm for South Asian and Chinese people, ≥85cm and ≥90cm for Japanese, and ≥90cm and 
85cm for Korean population (i.e. proposed by Korean Society for the Study of obesity) for males 
and females, respectively. In addition, South and Central Americans are recommended to use the 
cutoff point proposed to South Asians, and  Sub Saharan Africans, Eastern Mediterranean and 
middle East are recommended to use European data until more specific data are available (36). 
The classification power of WC to discriminate individuals with MetS and without MetS is 
determined using ROC curve analysis and the accuracy of the measurement is measured by the 
area under the ROC curve (AUC). Different studies reported different classification power of 
WC for males and females. For instance, in study from Mexico, the AUC of WC was 0.90 and 
0.80 for males and females, respectively (37). In study conducted in T2DM patients in Korea, the 
AUC value was 0.616 for males and 0.611 for females (38). In addition, age specific study 
conducted in Korean population, in elderly population the AUC was 0.620 in males and 0.626 in 
females, and for those who were 65 to 74 years old AUC was 0.664 and 0.658 for males and 
females respectively(37). Moreover, in study conducted in Japan showed that the AUC was 
0.669 and 0.739 for males and females respectively (39), and in China 0.736 and 0.705 for 
females and males respectively (40). The AUC in South Africa was 0.75 in males and 0.68 in 
females (41), in Egypt 0.693 in males and 0.683 in females (42), in Angola 0.85 for males and 
0.79 for females (43) and in Congolese community 0.899 in males and 0.844 in females (44).  
Different literatures supported that WC cutoff point is much variable among different ethnic 
groups and between genders. This is due to different cardiometabolic risk in different ethnic 
groups (35). For instance, a study of optimal WC cutoff point determination in relation to the 
amount of visceral adipose tissue in Five Latin American countries: Mexico, El Salvador, 
Venezuela, Colombia and Paraguay identified a WC threshold of 94 cm and 90-92 cm for men 
and women, respectively (37). Moreover, age specific study conducted in elderly Korean 
population, 2,224 participants aged 65 years and older found that optimal WC cutoff point to 
define MetS was 89.6 cm for males and 90.5 cm for females, and for those who were 65 to 74 
years old, it was 89.9 cm and 87.9 cm for males and females respectively (39). 
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The optimal cutoff points for WC for identifying the presence of IR and visceral obesity, as well 
as two or more metabolic components in Korean T2DM patients, were 87 cm for males and 81 
cm for females (38).  
A study conducted in general population in Japanese people using CT had also showed that cut 
off points of WC was 82.1cm for men and 78cm for women (40). Another study conducted in 
urban communities in Jinan and Jining Cities in China showed the WC cutoff point was 83.8 cm  
and 91.1 cm for females and males respectively (45).  
A cohort study was conducted on South African women to determine ethnic specific WC cutoff 
point for the diagnosis of the MetS. The result had found 91.5 cm cutoff point of WC for 
defining MetS (41).  On the other side, WC cutoff point was lower in South African study, which 
was 86 cm for men and 92 cm for women (46).  
Similarly, another cohort study conducted in South Africa reported that the cutoff points 
were91cm for males and 84cm for females. The report for Caucasian (white) men and women 
also showed WC cutoff point variation among Caucasian and African women; which was 97cm 
and 84cm, respectively (47). 
Another study was also done in T2DM black South African diabetic men. From the study, WC 
cutoff point above >90 cm was reported for T2DM black South African diabetic men as a 
predictor for the presence of at least two elements of the MetS (48). 
Egyptian has conducted a study aimed to identify WC cutoff points in normotensive and 
hypertensive patients. The result has indicated that WC value to define MetS was 93.5 cm for 
both Normotensive and hypertensive men and 91.5 and 92.5 cm for Normotensive and 
hypertensive women, respectively (49). Another study in adult Egyptians also showed that the 
optimal WC cutoffs were 100.5 and 96.25 cm for men and women, respectively (42). 
A cross sectional study in university employee in Luanda, Angola found an optimal WC cutoff 
point of 87.5 cm and 80.5 cm  for men and women respectively (50). In Congolese community, 
the highest values of WC for men and women were obtained for a threshold value of 95 cm for 
men and 99 cm in women (44).  
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1.4 Significance of the study  
International Diabetes Federation guidelines and the new harmonized guidelines have defined 
population specific WC cutoff point to define MetS.  However, for African population IDF has 
recommended to use the cutoff points derived from European population until the appropriate 
cutoff point is determined for African population. As a result, this study will provide insight 
about appropriateness of using the cutoff point of WC set by IDF.  
Moreover, different literatures support variation of WC cutoff points to define MetS among 
ethnicity difference and different segment of population. Therefore, the aim of this study is to 
determine WC cutoff point among T2DM patients in Ayder Comprehensive Specialized Hospital. 
This will help clinicians to avoid misclassification of T2DM who are at risk of MetS. The result 
will also be used as a baseline data for researchers to perform further studies.  
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2. OBJECTIVES 
 2.1 General objective  
 To determine WC cutoff point for defining MetS among T2DM patients in Ayder 
Comprehensive Specialized Hospital, Mekelle University, Tigray Region, Northern 
Ethiopia.  
 2.2 Specific objectives  
 To determine the classification power of WC among male T2DM patients for defining 
MetS 
 To determine the classification power of WC among female T2DM patients for defining 
MetS 
 To determine the cutoff point of WC among male T2DM patients for defining MetS 
 To determine the cutoff point of WC among female T2DM patients for defining MetS 
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3. HYPOTHESIS 
We hypothesized that there was a difference in WC cutoff point between T2DM patients in the 
study area and the IDF value recommended for the study population.  
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4. MATERIALS AND METHODS 
         4.1 Study area 
The study was conducted in Ayder Comprehensive Specialized Hospital, Mekelle University, 
which is located in the Northern part of Ethiopia in Mekelle city, Tigray Region. It is 783 km far 
from Addis Ababa. Ayder Comprehensive Specialized Hospital is a teaching hospital for College 
medicine and Health Sciences, Mekelle University. The Hospital is rendering its referral and 
non-referral services for around 8 million populations in its catchment areas of the Tigray, Afar 
and north-eastern parts of the Amhara regional state with total patient flow of above 100,000 per 
year. The Hospital is equipped with as the most advanced medical facility in the northern part of 
the country and it stands as the second largest hospital in the nation with a total capacity of 500 
inpatient beds. In diabetic clinic unit of the hospital, on average, about 2100 diabetic mellitus 
patients were serving in the hospital. Of these, 1600 (76.2%) diabetic patients were T2DM. 
      4.2 Study design and period  
Institution based cross sectional study was conducted from March to April 2017 in Ayder 
Comprehensive Specialized Hospital among T2DM patients. 
        4.3 Population  
                  4.3.1 Source population  
All T2DM patients registered at the diabetic clinic of Ayder Comprehensive Specialized 
Hospital. 
                  4.3.2 Study population  
All type II diabetic patients who were attending to the diabetic clinic of Ayder Comprehensive 
Specialized Hospital during the study period     
       4.4 Inclusion and exclusion criteria  
                       4.4.1 Inclusion criteria 
All T2DM patients 30 years and above who gave the informed consent were included in the 
study. 
11 
 
                      4.4.2 Exclusion criteria  
Diabetic patients who were not in the fasting state, patients with mental disorders and seriously 
ill patients were excluded from the study. Participants with any health condition or procedure 
that may alter the distribution of body fat compartments or the anatomy of the abdominal cavity 
such as pregnancy, recent laparotomy (≤8 days), invasive procedures in the abdomen, ascitis, and 
peritonitis were excluded from the study. Patients with co-morbidities such as TB and HIV were 
also excluded from the study. 
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4.5 Variable  
   4.5.1 Dependent variable  
Waist circumference 
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       4.6 Operational definitions    
Components of Mets are elevated Tg, BP, FBG, WC and reduced HDL-c  
Elevated Tg means_ Tg level ≥150 mg/dl or under treatment for hyper triglyceridemia. 
Reduced HDL-c means HDL-c level < 40 mg/dl in men and < 50 mg/dl in women  
Elevated BP means systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg 
or being under treatment for hypertension 
Elevated FBS means FBS ≥100 mg/dl or being under treatment for diabetes or being positive 
for T2DM.  
Cases mean T2DM patients with ≥1 abnormal components of MetS, excluding WC and FBS. 
Controls means T2DM patients without MetS components, excluding WC and FBS (51).  
Under weight: BMI <18.5 kg/m2 
Normal weight: BMI 18.5-24.99 kg/m2 
Over weight: BMI 25-29.99 kg/m2 
Obese: BMI ≥30kg/m2 
Youden index means (sensitivity + specificity – 1).  
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  4.7 Sample size and sampling technique 
Sample size was calculated based on the following formula: 
                                     
  =  
   
 
 
 
 (   )
  
  
Where:  n= number of study participants who were selected for each group (case and control) 
  (   )= 0.0099 Х   ( 
 )/  Х(6   + 16) 
    =  ᵠ  (   ) Х 1.414  
 
 
ᵠ
  
 = the inverse of standard cumulative normal distribution of AUC value (52). 
It is calculated by considering the assumptions of 5% margin of error, 95% level of confidence 
and, 0.899 and 0.844 AUC value of WC to classify cases from controls for male and female, 
respectively (44). A total of 520 study participants were selected using systematic sampling 
technique every 3 T2DM patients. The interval was obtained from the following formula and 
assumptions Kth =N/n, 1500/520=2.88~3 Where, “K” is the interval,  
             “N” is the total number of registered T2DM patients in the hospital who fulfilled the 
inclusion criteria which was 1500  
            “n” is the sample size (520).  
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          4.8 Data collection and laboratory methods 
        4.8.1   Socio-demographic data 
WHO modified STEPS questionnaire for NCD risk factors (version 1.4 questionnaires) was 
customized to collect socio-demographic and behavioral information. Patient data was obtained 
from routine hospital records of the diabetic clinic. During the study period, three clinical nurses 
were participated in collecting the patient information, and in measuring the anthropometric and 
clinical measurements.  
                 4.8.2 Anthropometric and blood pressure measurements   
Based on WHO STEPS protocol, WC measures were obtained from individuals wearing 
underwear at the end of several consecutive natural breaths, at a level parallel to the floor, 
midpoint between the top of the iliac crest and the lower margin of the last palpable rib in the 
mid axillary line (53, 54). Measurements were taken in duplicate and an average was calculated. 
If the difference between the two measurements was >1 cm, a third measurement was performed 
and the two closest values were used.  
The classification power of WC was measured by the AUC, which has a meaningful 
interpretation for disease classification from healthy subjects. The AUC interpreted as the 
probability that a randomly chosen diseased subject is rated or ranked as more likely to be 
diseased than a randomly chosen non diseased subject. This interpretation was based on 
nonparametric Mann-Whitney U statistics that is used in calculating AUC (55). Based on Mann-
Whitney U statistics, the maximum AUC=1 means that the diagnostic test is perfect, the 
AUC=0.8-0.9 is very good, the AUC= 0.7-0.8 is good and AUC=0.6-0.7 is poor  in the 
differentiation between the diseased and non diseased (56).  
Height and weight were measured with the subject in light clothing and no shoes, and BMI was 
calculated (kilograms per meter squared).Body mass index was measured as weight in kilograms 
divided by the square of their height in meter. Weight was measured while patients were wearing 
light clothing without shoes by using the weighing scale. Height measurement was taken using 
portable tape meter without shoes.  
Blood pressure was measured with a mercury sphygmomanometer after a 10 minute rest in the 
sitting position and the measurements was taken twice, 5 minute apart. The systolic and diastolic 
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blood pressures were measured. When the first two measurements differed by more than 
5mmHg, additional readings were measured and the average was taken (57). Participants were 
abstained from smoking and ingesting caffeine preceding 30 minutes measurement.  
               4.8.3 Sample collection and laboratory methods 
After an overnight fasting, 3 ml of venous blood sample was collected in a tube, preferably with 
gel following standard operating procedures (SOPs) by a qualified laboratory technologist. Blood 
samples were centrifuged after 30 minute of collection and serum sample was separated in to 
another test tube. Glucose, triglyceride and HDL-c levels in serum sample were analyzed on the 
day of sample collection by Pentra C400 clinical chemistry analyzer (HORIBA ABX SAS, 
France).  
Fasting serum glucose was measured using glucose oxidase method by colorimetry and 
triglyceride was determined based on an enzymatic colorimetric assay. In addition, HDL-c was 
measured using homogeneous enzymatic method for directly measuring of HDL-c level in serum 
without the need for any off-line pretreatment or centrifugation steps. The blood specimen was 
collected, processed and analyzed by two laboratory technologists. 
            4.8.4 Data quality control and management 
Pre-test was carried out in 10% of the total sample in the diabetic clinic of University of Gondar 
to evaluate the validity of the tool. Training was given to the data collectors by the principal 
investigator. In addition, the principal investigator had closely followed and frequently checked 
the data collection process to ensure the completeness and consistency of the collected data. 
Laboratory assays was carried out after running quality control samples. All procedures were 
done in accordance with the SOPs. The raw data (laboratory, clinical and demographic) was 
checked for completeness prior to entry to the software. The data was analyzed and interpreted 
by the principal investigator. 
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    4.9 Data analysis and interpretation  
Data were entered using Epi-info 3.5.1 and analyzed using SPSS version 20. Participants who 
had one or more abnormal MetS components (excluding WC and FBS), were code as case and 
the other as control (12, 58). The classification potential (AUC) of WC to distinguish cases from 
control was determined using ROC curve for both sexes separately. Sensitivity and specificity of 
WC to distinguish cases from controls was calculated at several WC points. For each WC point 
again, YI was computed. The WC point having the maximum YI was taken as the optimum 
cutoff point of WC to classify case from controls. In all conditions, P-value of < 0.05 was treated 
as statistically significant.  
   4.10 Ethical consideration 
Ethical clearance was obtained from the Research and Ethical Committee of School of 
Biomedical and Laboratory Sciences, University of Gondar. Letter of support was also secured 
from Ayder Referral Hospital. Written consent was obtained from the study participants after 
briefing on the aim and the voluntary nature of the study. Codes were used to keep the 
confidentiality of the study participants. The study participants were informed that they could 
receive their test results. Only the investigators were able to link the study participant’s identity 
with the code number. 
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5. RESULTS 
      5.1. Socio-demographic characteristics of T2DM patients 
Among the 520 study participants, 308 (59.2%) were females. The mean (± SD) age of the 
participants was 56 ± 10.8 years and 55 ± 11.4 years for males and females respectively.  
Majority of the participants 457/520 (87.9%) were from urban area (Table 1).  
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Table 1: Socio-demographic characteristics of diabetic patients at Ayder Comprehensive 
Specialized Hospital, Northern Ethiopia, 2017 (N=520) 
 
  Variables 
    
       Male  
      n (%) 
    Female  
    n (%) 
       Total 
       N(%) 
 
Age ( years) 
 
30-39     11(5.2)    18(5.8)        29(5.6) 
40-49     45(21.2)    81(26.3)        126(24.2) 
50-59     78(36.8)    95(30.8)        173(33.3) 
60-69      55(26.0)    76(24.7)        131(25.2) 
≥ 70      23(10.8)    38(12.4)        61(11.7) 
Occupation 
Governmental 
         
     80(37.7) 
           
   68(22.1) 
       
       148(28.5) 
Non- governmental      19(9.0)    13(4.2)        32(6.1) 
Self employee      68(32.0)    56(18.2)        124(23.8) 
House wife      0(0.0)    128(41.5)        128(24.6) 
Farmer      22(10.4)    11(3.6)        33(6.35) 
No      23(10.9)    32(10.4)        55(10.6) 
Marital status 
Single 
             
     17(8.0) 
             
    9(6.2) 
          
       36(6.9) 
Married      181(85.4)     212(68.8)        393(75.6) 
Divorced      8(3.8)     19(6.2)        27(5.2) 
Widowed      6(2.8)     58(18.8)        64(12.3) 
Ethnicity Tigray      208(98.1)     305(99.0)        513(98.6) 
Other      4(1.9)     3(1.0)        7(1.4) 
 
Educational level 
 
No formal schooling     29(13.7)    79(25.7)  108(20.7) 
Less than Primary school     14(6.6)      43(13.9) 57(10.8) 
Primary school completed     47(22.2)      60(19.5)   107(20.6) 
Secondary school completed      38(17.9)     53(17.2)  91(19.0) 
College/university completed     84(39.6)      73(23.7)    157(28.9) 
 
Residence 
 
 
Rural 
   29(13.7)      34(11.1)   63(12.2) 
Urban    183(86.3)      274(88.9)     457(87.8) 
 
Religion 
Orthodox  
  
   191(90.1) 
 
288(93.5) 
 
    479(92.1) 
Muslim    18(8.5)      18(5.8)        36(6.9) 
Other     3(1.4)      2(0.7) 5(1.0) 
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5.2 Clinical, behavioral and biochemical measurements of T2DM patients 
The mean duration of diagnosed diabetes was 4.7 ± 2.9 years for males and 4.6 ± 2.5years for 
females. All of the study participants have taken anti-diabetic drugs. Seventy two (35%) male 
and 144(46.8%) female participants were overweight and obese (Table 2).  
Table 2: Frequency of clinical, behavioral and anthropometric measurements of T2DM patients 
at Ayder Comprehensive Specialized hospital, Northern Ethiopia, 2017 (N=520) 
 
     Variables 
    
       Male  
      n(%) 
 
        Female 
         n(%) 
      Total 
      N (%) 
 
Medication status 
 
Anti-DM Only     123(58.02)     170(55.19)  293(56.35) 
 
Anti-DM +Anti-HT  34(16.04) 27(8.77)   61(11.73) 
Anti-DM +Anti-Dyslipidemia 
25(11.79) 58(18.83)  83(15.96) 
Anti-DM + HT + Anti-
Dyslipidemia 30(14.15) 53(17.21) 83(15.96) 
 
Duration of diabetes (Yrs) 
 
Less than one year 20(9.43)   25(8.13) 45(8.65) 
1-5 years 
101(47.64) 154(49.99) 255(49.05) 
6-10 years 
39(18.39) 75(24.35)    114(21.92) 
More than10 years 
52(24.54) 54(17.53) 106(20.38) 
     
 
Alcohol consumption 
 
Yes    46(21.69) 14(4.55) 60(11.54) 
No  166(78.31)     294(95.45)    460(88.46) 
     
 
Cigarette Smoking 
 
Yes 
5(2.35) 0(0.00) 5(0.96) 
No 207(97.65) 308(100) 515(99.04) 
  
             
 
   
BMI 
 
Under weight         11(5.00)         10(3.20)      21(4.00) 
Normal weight 
    129(60.00)     154(50.00)    283(54.50) 
Over weight 
65(31.70)     116(37.70) 181(34.80) 
Obese 
7(3.30)         28(9.10)  35(6.70) 
          DM= diabetic mellitus, HT= hypertension 
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Four hundred thirty six (275 Females and 161 Males) of the study participants were cases. 
Reduced HDL-c was the most prevailing abnormal component of MetS in both sexes which was 
221(42.5%), whereas, high blood pressure was the least, 157(30.2%) (Table 3). 
Table 3: Frequency of individual components of MetS among T2DM patients in Ayder 
Comprehensive Specialized Hospital, Northern Ethiopia, 2017 (n=520).   
Variables             Male             Female Total  (N%) 
n(%) 95 % CI    n(%) 95 % CI  
      
High TG   79(37.3) 30.7-44.0 134(56.5) 37.1-49.0      213(40.9) 
high BP   75(35.4) 28.9-42.3   82(26.6) 21.2-31.3      157(30.2) 
low HDL-c 116(54.7) 47.6-61.7 105(34.1) 20.6-47.6      221(42.5) 
 
Clusters of  abnormal components    
    
      
At least 1 component 161(75.9) 70.2-81.6 275(89.3) 85.4-92.4 436(83.8) 
At least 2 components   78(36.8) 30.7-43.5 131(42.5) 36.7-47.7 209(40.2) 
At least 3 components   57(26.9) 20.6-32.9 99(32.1) 27.3-37.2 156(30.0) 
All components   26(12.3) 7.9-16.7 45(14.6) 11.0-19.2   71(13.6) 
BP: Blood Pressure, HDL-c: High density lipoprotein cholesterol, TG: Triglyceride,  
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5.3 AUC, sensitivity and specificity of WC cutoff point to define MetS and metabolic risk 
factors  
The classification power of WC to define hypertension among the other MetS components was 
higher (0.67 in males and 0.63 in females) in both sexes in our study. However, the classification 
power of WC to define the reduced HDL-c was lower as compared to the other MetS 
components in both sexes (0.60 in males and 0.53 in females) (Table 4). 
Table 4:  Characteristics of ROC curves used for the identification of optimal WC cutoff values 
to define cases and MetS components among T2DM patients in Ayder Comprehensive 
Specialized Hospital, Northern Ethiopia, 2017 (N=520) 
Sex MetS components AUC  
(95% CI) 
Sensitivity Specificity P value 
Male Hypertension 0.67(0.60 -.75)     0.51 0.76  ≤0.001 
 Hypertriglyceridemia 0.67(.60 -.74)     0.49 0.76  ≤0.001 
 Low HDL-c 0.60(.52 -.67)     0.39 0.73    0.013 
 Cases 0.67(.58 -.75)     0.40 0.86 ≤ 0.001 
      
Female Hypertension 0.63(.56 -.70)     0.79 0.33   0.001 
 Hypertriglyceridemia 0.57(.52 -.65)     0.75 0.34   0.010 
 Low HDL-c 0.53(.44 -.61)     0.72 0.59 ≤0.001 
 Cases 0.63(.52-.73)     0.73 0.45   0.017 
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5.4 Classification power and optimum WC cutoff point of WCs to discriminate cases from 
controls  
Among the participants, 89.3% (275/308) of females and 75.9% (161/212) of males had at least 
one abnormal component of MetS (cases). The power of WC (AUC) to discriminate cases from 
control were 0.67(0.58-0.75) and 0.63(0.52-0.73) for males and females respectively; 
(Figure1).The optimal WC cutoff point to classify cases from controls was 95.5 cm and  87.5 cm 
for males and females respectively (Table 5). 
Table 5: Performance of different WCs for discriminating cases from controls among T2DM 
patients at Ayder Comprehensive Specialized hospital, Northern Ethiopia, 2017 (N=520) 
 
 
WC cutoff 
points (cm) 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
          PPV 
      (95%CI) 
   NPV 
(95%CI) 
Youden   
index  
Male 
(n=212) 
90 63.4 60.8            83.6      34.4 0.242 
92 54.4 70.6            85.3      32.7 0.250 
94 44.1 80.4            87.7      31.3 0.245 
95.5 39.8 86.3            90.1      31.2 0.261 
98 27.9 88.2            88.2      27.9 0.161 
100 21.7 92.2            89.7      27.2 0.139 
       
 
Female 
(308) 
 
80 
          
         88.4 24.2 
            
           87.3 
     
     20.0 0.126 
82          84.4 30.3            91.0      18.9 0.147 
85 81.4 36.4            91.4      19.0 0.178 
87.5 73.1 54.5            93.0      19.6 0.276 
88 70.9 54.5            92.8      18.4 0.254 
90 61.8 57.6            92.4      15.3 0.194 
CI= confidence interval, PPV= positive predictive value, NPV=negative predictive value  
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Figure 1 : ROC curves of WC to discriminate cases from controls among T2DM patients for both 
sexes in Ayder Comprehensive Specialized Hospital, Northern Ethiopia. 
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6. DISCUSSION 
Central obesity is the major component of metabolic risk factors.  WC is considered to be simple 
and inexpensive measure with excellent correlation with CT. As a good indicator of visceral fat, 
WC is widely used to predict the outcome of MetS by different organizations. In addition, WC 
cutoff values are age, gender and ethnicity specific for MetS. This study was aimed to determine 
WC classification power and cutoff point among T2DM patients for defining MetS.  
In the current study, WC had classified cases from controls with statistically significant power 
for both sexes (P-value= <0.001 and < 0.017 for males and females, respectively), and it had a 
poor classification power to categorize cases from controls in both sexes. The optimal WC cutoff 
value was 87.5 cm (sensitivity 73.1% and specificity 54.5%) for females and 95.5 cm (sensitivity 
39.8%   and specificity 86.3 %) for males for identifying cases from controls.  
Even though the classification power of WC was statistically significant, it had poor 
classification power (for males AUC=0.67;95% CI: 0.58-0.75, for females AUC =0.63;95% CI 
0.52-0.73) to discriminate cases from controls (56). Similar to our study, the classification power 
of WC to classify cases from control was poor in a study conducted on Benin. It was 0.67 for 
males and 0.68 for females (59). Moreover, a finding reported from Egypt  was also 0.69 for 
males and 0.63 for females (60).  
On the contrary, in several studies such as in Angola (0.85 in males and 0.79 in females) (43), 
and in Congolese adults (0.899 in males and 0.844 in females) (44), WC had a good 
classification power to classify cases from control in both sexes. 
In our study, the optimal WC cutoff point that best predicts cases was 95.5 cm for the T2DM 
males, which is relatively higher than the value for females. The finding from the present study is 
slightly higher than the IDF recommended value for males, which is 94 cm (12). 
In contrast to our study,  WC cutoff point in urban African teachers was  90cm in men (61) and 
the same to that in black South African T2DM male patients were also 90cm (48). These values 
were somewhat different to that found in T2DM male patients in our study area.   
  
26 
 
The WC cutoff value for T2DM females determined in this study is 87.5cm which is similar to 
study in university employee in Angola (87.5cm) (62). The result from this study was higher 
than the recommended cutoff points to define cases for African females, which is ≥80cm. In 
contrast, our finding is lower than the study conducted for African females, which was 98 cm 
(61) and in study from Egyptian adults, which was 96.25cm (60).  
The present study suggested that WC cutoff point for females shows lower than males, which is 
in line to the recommended value. Some studies report shows that WC cutoff point for African 
population is higher in rural south African females (92cm) than males (86cm)(41),in Cape Town 
94cm for females and 83.9cm for males (63). Similarly,  in Benin  94 cm for females and 80cm 
for males, which is the exact reverse of the recommended value (64). Furthermore, a study in 
Congolese community also shows high WC value in females (99 cm) as compared to males 
(95cm) (44).   
In general, several studies in Africa that conducted to determine WC cutoff point showed an 
increased WC value in females as compared to males. On the contrary, our finding is higher in 
males than females, which is in line to the IDF. On the other hand, study from Tunisian adults 
showed equal value of WC for both males and females which was 85 cm (65). Although the WC 
value in adult Egyptian females (96.25cm) wasn’t higher than males (100.5cm), it shows higher 
than the IDF recommended value for African females (60).  
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7. CONCLUSION 
The power of WC value to classify cases from controls was poor and the cutoff points of WC 
were 87.5 cm and 95.5 cm for females and males respectively. 
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8. RECOMMENDATION 
Further study in prospective cohort is better to determine the optimal WC cutoff point among 
T2DM patients to define MetS. In addition, studies which can consider the confounders such as 
lipid lowering medications, age of the participants and duration of diabetes are advisable in order 
to increase the classification power of WC. 
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9. LIMITATION 
In our study the discriminating power of WC to classify cases from controls was poor. The 
possible reasons for the poor classification power of WC could be due to the confounders such as 
statin medication, age of the particpants and duration of diabetes, were not considered.  
 
  
30 
 
        10. REFERENCES  
1. Syed Mohd Razi Gutch Manish, Gupta Kumar Keshav, Kumar Sukriti, Gupta A. Site or Size of 
Waist Circumference, Which one is More important in Metabolic Syndrome? Int J Med Public 
Health. 2016;6(2):69-72. 
2. Alshehri AM. Metabolic syndrome and cardiovascular risk. Journal of Family and Community 
Medicine. 2010;17(2):73. 
3. Pedrinelli R, Dell’Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an 
integrated marker of cardiovascular risk in essential hypertension. Journal of human 
hypertension. 2002;16(2):79-89. 
4. Fezeu L, Balkau B, Kengne A-P, Sobngwi E, Mbanya J-C. Metabolic syndrome in a sub-Saharan 
African setting: central obesity may be the key determinant. Atherosclerosis. 2007;193(1):70-6. 
5. Organization WH. Obesity and overweight [Fact sheet]; updated June 2016. Trouvé le. 2016;13. 
6. Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities? 
Mechanisms of association. Arquivos Brasileiros de Endocrinologia & Metabologia. 
2014;58(6):600-9. 
7. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-
abdominal fat is a major determinant of the National Cholesterol Education Program Adult 
Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53(8):2087-94. 
8. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and 
abdominal adiposity and risk of death in Europe. New England Journal of Medicine. 
2008;359(20):2105-20. 
9. Van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. 
International journal of obesity and related metabolic disorders: journal of the International 
Association for the Study of Obesity. 1993;17(4):187-96. 
10. Sanches FM, Avesani CM, Kamimura MA, Lemos MM, Axelsson J, Vasselai P, et al. Waist 
circumference and visceral fat in CKD: a cross-sectional study. American Journal of Kidney 
Diseases. 2008;52(1):66-73. 
11. Ma W-Y, Yang C-Y, Shih S-R, Hsieh H-J, Hung CS, Chiu F-C, et al. Measurement of Waist 
Circumference Midabdominal or iliac crest? Diabetes care. 2013;36(6):1660-6. 
12. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the 
metabolic syndrome. Circulation. 2009;120(16):1640-5. 
13. LIMT SS, VOS T, FLAXMAN AD, DANAEI G, SHIBUYA K, ADAIR-ROHANI H, et al. A 
comparative risk assessment of burden of disease and injury attributable to 67 risk factors and 
risk factor clusters in 21 regions, 1990―2010: a systematic analysis for the Global Burden of 
Disease Study 2010. Lancet. 2013;380(9859):2224-60. 
14. de Oliveira A, Cocate PG, Hermsdorff HHM, Bressan J, de Silva MF, Rodrigues JA, et al. Waist 
circumference measures: cutoff analyses to detect obesity and cardiometabolic risk factors in a 
Southeast Brazilian middle-aged men population-a cross-sectional study. Lipids in health and 
disease. 2014;13(1):1. 
15. Unwin N, Whiting D, Guariguata L. International Diabetes Federation. IDF diabetes atlas. 
Brussels, Belgium: International Diabetes Federation; 2012. 2013. 
16. Tuei VC, Maiyoh GK, Ha CE. Type 2 diabetes mellitus and obesity in sub‐Saharan Africa. 
Diabetes/metabolism research and reviews. 2010;26(6):433-45. 
17. Gao HX, Regier EE, Close KL. International Diabetes Federation World Diabetes Congress 
2015. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. 
31 
 
18. Kasen S, Cohen P, Chen H, Must A. Obesity and psychopathology in women: a three decade 
prospective study. International Journal of Obesity. 2008;32(3):558-66. 
19. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, 
obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives 
of general psychiatry. 2010;67(3):220-9. 
20. Roberts RE, Deleger S, Strawbridge WJ, Kaplan GA. Prospective association between obesity 
and depression: evidence from the Alameda County Study. International journal of obesity. 
2003;27(4):514-21. 
21. Abelson P, Kennedy D. The obesity epidemic. Science. 2004;304(5676):1413-. 
22. Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and 
projections to 2030. International journal of obesity. 2008;32(9):1431-7. 
23. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and 
national prevalence of overweight and obesity in children and adults during 1980–2013: a 
systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 
2014;384(9945):766-81. 
24. Wilborn C, Beckham J, Campbell B, Harvey T, Galbreath M, La Bounty P, et al. Obesity: 
prevalence, theories, medical consequences, management, and research directions. Journal of the 
International Society of Sports Nutrition. 2005;2(2):1. 
25. Witkowski TH. Food marketing and obesity in developing countries: analysis, ethics, and public 
policy. Journal of macromarketing. 2007;27(2):126-37. 
26. Daousi C, Casson I, Gill G, MacFarlane I, Wilding J, Pinkney J. Prevalence of obesity in type 2 
diabetes in secondary care: association with cardiovascular risk factors. Postgraduate medical 
journal. 2006;82(966):280-4. 
27. Thomas MC, Zimmet P, Shaw JE. Identification of Obesity in Patients With Type 2 Diabetes 
From Australian Primary Care The NEFRON-5 Study. Diabetes care. 2006;29(12):2723-5. 
28. Alqurashi K, Aljabri K, Bokhari S. Prevalence of diabetes mellitus in a Saudi community. 
Annals of Saudi medicine. 2011;31(1):19. 
29. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab 
Syndr Obes. 2010;3(1):285-95. 
30. Stern M, Williams K, : G-VCea. Does the metabolic syndrome  improve identifi cation of 
individuals heart disease and diabetes in the West  of Scotland Coronary Prevention Study. 
2003;108:414-9. 
31. Mowar A, Amit V, Tanvi S, Nigam P. Prevalence of Metabolic Syndrome in Type 2 Diabetes 
Mellitus Patients in Tertiary care Hospital of Rohelkhand of UP (Bareilly). jornal of medical 
science and clinical research. 2015;03(07):6856-60|. 
32. Federation ID. The IDF consensus worldwide definition of the metabolic syndrome. Belgium; 
2006[Links]. 2005. 
33. Alebiosu CO, Odusan BO. Metabolic syndrome in subjects with type-2 diabetes mellitus. Journal 
of the National Medical Association. 2004;96(6):817. 
34. Kengne AP, Limen SN, Sobngwi E, Djouogo CF, Nouedoui C. Metabolic syndrome in type 2 
diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan 
Africans. Diabetology & metabolic syndrome. 2012;4(1):22. 
35. Ness-Abramof R, Apovian CM. Waist circumference measurement in clinical practice. Nutrition 
in Clinical Practice. 2008;23(4):397-404. 
36. Manish SMRG, Keshav GK, Sukriti K, Gupta A. Site or Size of Waist Circumference, Which 
one is More important in Metabolic Syndrome? Int J Med Public Health. 2016;6(2):69-72. 
32 
 
37. Aschner P, Buendía R, Brajkovich I, Gonzalez A, Figueredo R, Juarez XE, et al. Determination 
of the cutoff point for waist circumference that establishes the presence of abdominal obesity in 
Latin American men and women. Diabetes research and clinical practice. 2011;93(2):243-7. 
38. Jung Soo Lim1 YJC, Soo-Kyung Kim3, Byoung Wook Huh2, Eun Jig Lee4, Kap Bum Huh2. 
Optimal Waist Circumference Cutoff Value Based on Insulin Resistance and Visceral Obesity in 
Koreans with Type 2 Diabetes. Diabetes Metab J. 2015;;39::253-63. 
39. So ES, Yoo KS. Waist circumference cutoff points for central obesity in the Korean elderly 
population. Journal of Applied Gerontology. 2015;34(1):102-17. 
40. Tsukiyama H, Nagai Y, Matsubara F, Shimizu H, Iwamoto T, Yamanouchi E, et al. Proposed 
cut‐off values of the waist circumference for metabolic syndrome based on visceral fat volume in 
a Japanese population. Journal of diabetes investigation. 2016. 
41. Motala AA, Esterhuizen T, Pirie FJ, Omar MA. The prevalence of metabolic syndrome and 
determination of the optimal waist circumference cutoff points in a rural South African 
community. Diabetes care. 2011;34(4):1032-7. 
42. Samir H. Assaad-Khalil ea. Optimal waist circumference cutoff points for the determination of 
abdominal obesity and detection of cardiovascular risk factors among adult Egyptian population. 
Indian J Endocr Metab 2015; 19:804-10. 
43. Magalhães P, Capingana DP, Mill JG. Prevalence of the metabolic syndrome and determination 
of optimal cut-off values of waist circumference in university employees from Angola: 
cardiovascular topic. Cardiovascular journal of Africa. 2014;25(1):27-33. 
44. Katchunga PB, Hermans M, Bamuleke BA, Katoto PC, Kabinda JM. Relationship between waist 
circumference, visceral fat and metabolic syndrome in a Congolese community: further research 
is still to be undertaken. Pan African Medical Journal. 2013;14(1). 
45. HOU XG, Chuan W, Qiang Z, YANG WF, WANG JX, LI CQ, et al. Optimal waist 
circumference cut-off values for identifying metabolic risk factors in middle-aged and elderly 
subjects in shandong province of China. Biomedical and Environmental Sciences. 
2014;27(5):353-9. 
46. Crowther NJ, Norris SA. The current waist circumference cut point used for the diagnosis of 
metabolic syndrome in sub-Saharan African women is not appropriate. PLoS One. 
2012;7(11):e48883. 
47. Hoebel S, Malan L, De Ridder J. Determining ethnic-, gender-, and age-specific waist 
circumference cut-off points to predict metabolic syndrome: the Sympathetic Activity and 
Ambulatory Blood Pressure in Africans (SABPA) study. Journal of Endocrinology, Metabolism 
and Diabetes of South Africa. 2013;18(2):88-96. 
48. Kalk WJ, Joffe BI, Sumner AE. The waist circumference of risk in black South African men is 
lower than in men of European ancestry. Metabolic syndrome and related disorders. 
2011;9(6):491-5. 
49. Ibrahim MM, Elamragy AA, Girgis H, Nour MA. Cut off values of waist circumference & 
associated cardiovascular risk in Egyptians. BMC cardiovascular disorders. 2011;11(1):1. 
50. Magalhães P, Capingana DP, Mill JG. Prevalence of the metabolic syndrome and determination 
of optimal cut-off values of waist circumference in university employees from Angola. 
Cardiovascular journal of Africa. 2014;25(1):27. 
51. Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K. Harmonizing the metabolic 
syndrome. A joint interim statement of the IDF Task Force on Epidemiology and Prevention; 
NHL and Blood Institute; AHA; WHF; IAS; and IA for the Study of Obesity. Circulation. 
2009;120(16):1640-5. 
33 
 
52. Kumar R, Indrayan A. Receiver operating characteristic (ROC) curve for medical researchers. 
Indian pediatrics. 2011;48(4):277-87. 
53. Consultation WE. Waist circumference and waist-hip ratio. Report of a WHO Expert 
Consultation Geneva: World Health Organization. 2008:8-11. 
54. Organization WH. Waist circumference and waist-hip ratio: Report of a WHO expert 
consultation, Geneva, 8-11 December 2008. 2011. 
55. Hanley JA MB. The meaning and use of the area under a receiver operating characteristic (ROC) 
curve. Radiology. 1982;;143:: 29-36. 
56. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic 
test evaluation. Caspian journal of internal medicine. 2013;4(2):627. 
57. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 
Canadian Hypertension Education Program recommendations for blood pressure measurement, 
diagnosis, assessment of risk, prevention, and treatment of hypertension. Canadian Journal of 
Cardiology. 2014;30(5):485-501. 
58. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. 
Circulation. 2004;109(3):433-8. 
59. Agueh VD, Sossa C, Ouendo DM-E, Paraizo NM, Azandjemè C, Kpozehouen A, et al. 
Determination of the optimal waist circumference cut-off points in Benin adults. Open Journal of 
Epidemiology. 2015;5(04):217. 
60. Assaad-Khalil SH, Mikhail MM, Aati TA, Zaki A, Helmy MA, Megallaa MH, et al. Optimal 
waist circumference cutoff points for the determination of abdominal obesity and detection of 
cardiovascular risk factors among adult Egyptian population. Indian journal of endocrinology 
and metabolism. 2015;19(6):804. 
61. Prinsloo J, Malan L, De Ridder J, Potgieter J, Steyn H. Determining the waist circumference cut 
off which best predicts the metabolic syndrome components in urban Africans: the SABPA 
study. Experimental and clinical endocrinology & diabetes. 2011;119(10):599-603. 
62. Pedro Magalhães DPC, José G Mill. Prevalence of the metabolic syndrome and determination of 
optimal cutoff values of waist circumference in university employees from Angola. 
Cardiovascular journal of Africa. 2014; 25(1). 
63. Peer N, Steyn K, Levitt N. Differential obesity indices identify the metabolic syndrome in Black 
men and women in Cape Town: the CRIBSA study. Journal of Public Health. 2016;38(1):175-
82. 
64. Mabchour AE, Delisle H, Vilgrain C, Larco P, Sodjinou R, Batal M. Specific cut-off points for 
waist circumference and waist-to-height ratio as predictors of cardiometabolic risk in Black 
subjects: a cross-sectional study in Benin and Haiti. Diabetes, metabolic syndrome and obesity: 
targets and therapy. 2015;8:513. 
65. Bouguerra R, Alberti H, Smida H, Salem L, Rayana C, El Atti J, et al. Waist circumference 
cut‐off points for identification of abdominal obesity among the Tunisian adult population. 
Diabetes, Obesity and Metabolism. 2007;9(6):859-68. 
 
 
  
34 
 
Declaration  
I, the undersigned, Clinical Chemistry MSc. student declare that this thesis paper is my original 
proposal for fulfillment of the requirements for degree of Master of Science in Clinical 
Chemistry.  
Name: Shewit H/mariam  
     Signature: ________________ 
Place of submission: Department of Clinical Chemistry, School of Biomedical and Laboratory 
Sciences, College of Medicine and Health Science, University of Gondar  
Date of submission: ___________________ 
This thesis proposal will be submitted for confirmation with my / our approval as University 
advisor (s) 
Advisors  
1. Mr. Molla Abebe (MSc.): Sign: _________  Date:______________ 
2. Mr. Tadele Melak (MSc):   Sign: __________  Date:______________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
ASSURANCE OF INVESTIGATOR 
The undersigned agrees to accept responsibility for the scientific, ethical and technical conduct 
of the research project and for provision of required progress reports as pre-terms and conditions 
of the research and publications office of the University of Gondar. 
 
Name of the student:      
Date:      Signature:     
 
Approval of the advisor (s) 
Advisors 
 Name          Signature           Date 
1 Mr. Molla Abebe (Ass.prof)                                   
 
2. Mr. Tadele Melak (MSc)                 
 
Examiners 
Name          Signature           Date 
1.             
2.            
 
 
